Technical Analysis for DRNA - Dicerna Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 19.29 -1.93% -0.38
DRNA closed down 1.93 percent on Friday, October 23, 2020, on 51 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Nov 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down
Historical DRNA trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
20 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Crossed Above 20 DMA Bullish -1.93%
Bollinger Band Squeeze Range Contraction -1.93%
20 DMA Resistance Bearish 1.26%
50 DMA Support Bullish 1.26%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.26%
Older End-of-Day Gignals for DRNA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below 20 DMA 2 days ago
20 DMA Support 2 days ago
Down 2 % 2 days ago
10 DMA Resistance 2 days ago
Down 1% 2 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company's development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including maple syrup urine disease, familial amyloid polyneuropathy or cardiomyopathy, alpha-1 anti-trypsin hepatocyte inclusions, hemophilia A and B, paroxysmal nocturnal hemoglobinuria, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated; and a product candidate targeting the oncogene KRAS. The company has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of DsiRNA molecules and drug delivery technologies for therapeutic targets in oncology; and a license agreement with City of Hope, an academic research and medical center, to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.
Medicine Biopharmaceutical Cancer Diseases Disease Cancers Enzymes Liver Liver Diseases Paroxysmal Nocturnal Hemoglobinuria Cardiomyopathy Carcinogenesis Familial Amyloid Polyneuropathy Ras Subfamily C Met Drug Delivery Technologies Hemophilia A Hyperoxaluria Primary Hyperoxaluria Treatment Of Various Cancers

Is DRNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 27.68
52 Week Low 11.75
Average Volume 551,848
200-Day Moving Average 20.43
50-Day Moving Average 18.85
20-Day Moving Average 19.24
10-Day Moving Average 19.66
Average True Range 0.99
ADX 14.14
+DI 17.72
-DI 17.98
Chandelier Exit (Long, 3 ATRs ) 18.09
Chandelier Exit (Short, 3 ATRs ) 20.72
Upper Bollinger Band 20.72
Lower Bollinger Band 17.77
Percent B (%b) 0.52
BandWidth 15.30
MACD Line 0.17
MACD Signal Line 0.18
MACD Histogram -0.0127
Fundamentals Value
Market Cap 1.44 Billion
Num Shares 74.5 Million
EPS -1.38
Price-to-Earnings (P/E) Ratio -14.02
Price-to-Sales 15.59
Price-to-Book 9.03
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.16
Resistance 3 (R3) 20.21 19.97 20.02
Resistance 2 (R2) 19.97 19.75 19.95 19.97
Resistance 1 (R1) 19.63 19.61 19.51 19.58 19.92
Pivot Point 19.39 19.39 19.33 19.37 19.39
Support 1 (S1) 19.05 19.17 18.93 19.00 18.66
Support 2 (S2) 18.81 19.03 18.79 18.61
Support 3 (S3) 18.47 18.81 18.57
Support 4 (S4) 18.42